What’s missing in patient-reported outcome reporting? A scoping review and aggregated trial-level analysis of completion rates in oncology randomized controlled trials
PRO completion rates in cancer RCTs remain challenging as they vary across settings, particularly beyond baseline, and reporting on missing data is often inadequate. These findings highlight the need for improved reporting and greater prioritization of PRO completion regardless of trial design.
Authors
- Samuel Vorbach (ORCID: https://orcid.org/0009-0003-1711-1604)
- Lotte van der Weijst (ORCID: https://orcid.org/0000-0001-8658-1894)
- Johannes M. Giesinger (ORCID: https://orcid.org/0000-0003-2744-5950)
- Monika Sztankay (ORCID: https://orcid.org/0000-0002-7938-1250)
- Abigirl Machingura (ORCID: https://orcid.org/0000-0003-0289-9614)
- madeline pe
- Jens Lehmann (ORCID: https://orcid.org/0000-0002-4670-7517)
- Daniela Krepper (ORCID: https://orcid.org/0009-0009-0026-9548)
- N.J. Hubel (ORCID: https://orcid.org/0009-0003-5501-1583)
- Deborah Fitzsimmons
- Bernhard Holzner
- Claudia Seidl
- Scottie Kern
Institutions
- Innsbruck Medical University (AT)
- European CanCer Organisation (BE)
- Critical Path Institute (US)
- Swansea University (GB)
- European Organisation for Research and Treatment of Cancer (BE)
- University Hospital Innsbruck (AT)
Publication Details
- Journal
- Critical Reviews in Oncology/Hematology
- Published
- 2025-12-23
- DOI
- https://doi.org/10.1016/j.critrevonc.2025.105100
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00